Bormioli Pharma, a leading name in the pharmaceutical packaging industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 1927, the company has established itself as a pioneer in the design and production of glass and plastic containers, primarily serving the pharmaceutical, healthcare, and cosmetic sectors. Bormioli Pharma is renowned for its innovative solutions, including high-quality vials, bottles, and closures that ensure product safety and integrity. The company’s commitment to sustainability and advanced manufacturing processes sets it apart in a competitive market. With a strong focus on research and development, Bormioli Pharma has achieved significant milestones, solidifying its position as a trusted partner for global pharmaceutical companies.
How does Bormioli Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bormioli Pharma's score of 46 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Bormioli Pharma reported total carbon emissions of approximately 134,185,000 kg CO2e, which includes Scope 1 and 2 emissions. The company’s Scope 3 emissions were approximately 95,334,000 kg CO2e, with significant contributions from purchased goods and services (about 61,598,000 kg CO2e) and end-of-life treatment of sold products (approximately 10,654,000 kg CO2e). Bormioli Pharma has set ambitious reduction targets, aiming for a 30% reduction in CO2 emissions for both Scope 1 and Scope 2 by 2030, compared to 2021 levels. This commitment reflects the company's proactive approach to climate action and aligns with industry standards for sustainability. The emissions data is cascaded from its parent company, Bormioli Pharma S.p.a., which is part of a broader corporate family that includes Gerresheimer AG. This relationship influences Bormioli Pharma's climate strategies and reporting practices. Overall, Bormioli Pharma is focused on reducing its carbon footprint while navigating the complexities of emissions across its operational scopes.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | - | - | - | - |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Bormioli Pharma's Scope 3 emissions, which increased by 13% last year and increased by approximately 13% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" being the largest emissions source at 65% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bormioli Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.